The funds will advance an idiopathic pulmonary fibrosis medicine once owned by Eli Lilly and an antibody-drug conjugate the startup licensed from another biotech.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,